CTLA4 and melanoma: The Lenvamel study aimed to investigate the efficacy and safety of lenvatinib combined with anti-PD-1 in a French multicenter real-world patient cohort with advanced melanoma refractory to prior treatment with anti-PD-1 with or without anti-CTLA-4.